| dc.contributor.author |
Mukherji D. |
| dc.contributor.author |
Pezaro C.J. |
| dc.contributor.author |
Shamseddine A. |
| dc.contributor.author |
De Bono J.S. |
| dc.contributor.editor |
|
| dc.date |
Oct-2013 |
| dc.date.accessioned |
2017-10-05T15:42:00Z |
| dc.date.available |
2017-10-05T15:42:00Z |
| dc.date.issued |
2013 |
| dc.identifier |
10.1016/j.ctrv.2012.12.004 |
| dc.identifier.isbn |
|
| dc.identifier.issn |
03057372 |
| dc.identifier.uri |
http://hdl.handle.net/10938/18278 |
| dc.description.abstract |
Prostate cancer is a common disease amongst elderly men. Compared with younger patients, men over the age of 75 are more likely to present with advanced disease and have a greater risk of death from prostate cancer despite higher death rates from competing causes. Treatment options for advanced prostate cancer have improved considerably in the last two years. The immunotherapy sipuleucel-T, the cytotoxic cabazitaxel, the androgen biosynthesis inhibitor abiraterone acetate, the radioisotope radium-223 and the antiandrogen enzalutamide have all been shown to improve survival in randomized phase III studies for patients with metastatic castration-resistant prostate cancer. This review will focus on the clinical data regarding new treatment developments specifically applied to elderly patients with advanced prostate cancer. © 2012 . |
| dc.format.extent |
|
| dc.format.extent |
Pages: (578-583) |
| dc.language |
English |
| dc.publisher |
OXFORD |
| dc.relation.ispartof |
Publication Name: Cancer Treatment Reviews; Publication Year: 2013; Volume: 39; no. 6; Pages: (578-583); |
| dc.relation.ispartofseries |
|
| dc.relation.uri |
|
| dc.source |
Scopus |
| dc.subject.other |
|
| dc.title |
New treatment developments applied to elderly patients with advanced prostate cancer |
| dc.type |
Review |
| dc.contributor.affiliation |
Mukherji, D., Department of Hematology-Oncology, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon |
| dc.contributor.affiliation |
Pezaro, C.J., Prostate Targeted Therapy Group, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM25PT, United Kingdom |
| dc.contributor.affiliation |
Shamseddine, A., Department of Hematology-Oncology, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon |
| dc.contributor.affiliation |
De Bono, J.S., Prostate Targeted Therapy Group, The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey SM25PT, United Kingdom |
| dc.contributor.authorAddress |
Mukherji, D.; Department of Hematology-Oncology, American University of Beirut Medical Center, P.O. Box 11-0236, Riad El Solh, Beirut 1107 2020, Lebanon; email: Dm25@aub.edu.lb |
| dc.contributor.authorCorporate |
University: American University of Beirut Medical Center; Faculty: Faculty of Medicine; Department: Internal Medicine; Division: Hematology-Oncology; |
| dc.contributor.authorDepartment |
Internal Medicine |
| dc.contributor.authorDivision |
Hematology-Oncology |
| dc.contributor.authorEmail |
Dm25@aub.edu.lb; Carmel.pezaro@icr.ac.uk; As04@aub.edu.lb; johann.de-bono@icr.ac.uk |
| dc.contributor.faculty |
Faculty of Medicine |
| dc.contributor.authorInitials |
Mukherji, D |
| dc.contributor.authorInitials |
Pezaro, CJ |
| dc.contributor.authorInitials |
Shamseddine, A |
| dc.contributor.authorInitials |
De Bono, JS |
| dc.contributor.authorOrcidID |
|
| dc.contributor.authorReprintAddress |
Mukherji, D (reprint author), Amer Univ Beirut, Med Ctr, Dept Hematol Oncol, POB 11-0236, Beirut 11072020, Lebanon. |
| dc.contributor.authorResearcherID |
|
| dc.contributor.authorUniversity |
American University of Beirut Medical Center |
| dc.description.cited |
Armstrong AJ, 2011, J CLIN ONCOL S7, V29; Attard G, 2008, J CLIN ONCOL, V26, P4563, DOI 10.1200-JCO.2007.15.9749; Aventis S, 2011, JEVTANA PRESCRIBING; Bahl A, 2012, J CLIN ONCOL S5, V30, P44; BARRIE SE, 1994, J STEROID BIOCHEM, V50, P267, DOI 10.1016-0960-0760(94)90131-7; Basch E, 2012, J CLIN ONCOL; Bok Robert A., 1999, Drug Safety, V20, P451, DOI 10.2165-00002018-199920050-00005; Dall'era MA, 2012, EUR UROL; Danila DC, 2010, J CLIN ONCOL, V28, P1496, DOI 10.1200-JCO.2009.25.9259; de Bono J, 2012, J CLIN ONCOL S, V30; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016-S0140-6736(10)61389-X; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056-NEJMoa1014618; Dendreon, 2011, PROV PRESCR INF; Droz JP, 2010, BJU INT, V106, P462, DOI 10.1111-j.1464-410X.2010.09334.x; Fizazi K, 2011, LANCET, V377, P813, DOI 10.1016-S0140-6736(10)62344-6; Heidenreich A, 2012, EUR UROL; Higano CS, 2009, CANCER, V115, P3670, DOI 10.1002-cncr.24429; Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322-caac.20073, 10.1002-caac.20073]; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056-NEJMoa1001294; La Vecchia C, 2010, ANN ONCOL, V21, P1323, DOI 10.1093-annonc-mdp530; Longo DL, 2010, NEW ENGL J MED, V363, P479, DOI 10.1056-NEJMe1006300; LUTHY IA, 1988, J STEROID BIOCHEM, V31, P845, DOI 10.1016-0022-4731(88)90295-6; Marbury T, 2011, EUR J CANCER, V47, pS502; Mita AC, 2009, CLIN CANCER RES, V15, P723, DOI 10.1158-1078-0432.CCR-08-0596; Parker C., 2011, EUR MULT CANC C 2011; Pezaro CJ, 2012, J CLIN ONCOL, V30; POTTER GA, 1995, J MED CHEM, V38, P2463, DOI 10.1021-jm00013a022; Reid AHM, 2010, J CLIN ONCOL, V28, P1489, DOI 10.1200-JCO.2009.24.6819; Ryan CJ, 2011, CLIN CANCER RES, V17, P4854, DOI 10.1158-1078-0432.CCR-11-0815; Ryan CJ, 2010, J CLIN ONCOL, V28, P1481, DOI 10.1200-JCO.2009.24.1281; Ryan CJ, 2012, N ENGL J MED; Saad F, 2002, J NATL CANCER I, V94, P1458; Saad F, 2007, CANCER, V110, P1860, DOI 10.1002-cncr.22991; Saad F, 2012, J CLIN ONCOL S, V30; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016-S0140-6736(10)60172-9; Scher HI, 2011, J CLIN ONCOL S, V29; Scher HI, 2012, N ENGL J MED; Scosyrev E, 2012, CANCER-AM CANCER SOC, V118, P3062, DOI 10.1002-cncr.26392; Shahinian VB, 2005, NEW ENGL J MED, V352, P154, DOI 10.1056-NEJMoa041943; Smith MR, 2009, NEW ENGL J MED, V361, P745, DOI 10.1056-NEJMoa0809003; Snedecor SJ, 2011, J CLIN ONCOL S, V29; Sternberg CN, 2011, EUR J CANCER, V47, pS488; Sundar S, 2012, BMJ CASE REP, V2012; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126-science.1168175 |
| dc.description.citedCount |
3 |
| dc.description.citedTotWOSCount |
4 |
| dc.description.citedWOSCount |
4 |
| dc.format.extentCount |
6 |
| dc.identifier.articleNo |
|
| dc.identifier.coden |
CTRED |
| dc.identifier.pubmedID |
23290885 |
| dc.identifier.scopusID |
84878937422 |
| dc.identifier.url |
|
| dc.publisher.address |
THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND |
| dc.relation.ispartofConference |
|
| dc.relation.ispartofConferenceCode |
|
| dc.relation.ispartofConferenceDate |
|
| dc.relation.ispartofConferenceHosting |
|
| dc.relation.ispartofConferenceLoc |
|
| dc.relation.ispartofConferenceSponsor |
|
| dc.relation.ispartofConferenceTitle |
|
| dc.relation.ispartofFundingAgency |
|
| dc.relation.ispartOfISOAbbr |
Cancer Treat. Rev. |
| dc.relation.ispartOfIssue |
6 |
| dc.relation.ispartOfPart |
|
| dc.relation.ispartofPubTitle |
Cancer Treatment Reviews |
| dc.relation.ispartofPubTitleAbbr |
Cancer Treat. Rev. |
| dc.relation.ispartOfSpecialIssue |
|
| dc.relation.ispartOfSuppl |
|
| dc.relation.ispartOfVolume |
39 |
| dc.source.ID |
WOS:000321317200004 |
| dc.type.publication |
Journal |
| dc.subject.otherAuthKeyword |
Abiraterone |
| dc.subject.otherAuthKeyword |
Alpharadin |
| dc.subject.otherAuthKeyword |
Cabazitaxel |
| dc.subject.otherAuthKeyword |
Castration resistant prostate cancer |
| dc.subject.otherAuthKeyword |
CRPC |
| dc.subject.otherAuthKeyword |
Denosumab |
| dc.subject.otherAuthKeyword |
Elderly |
| dc.subject.otherAuthKeyword |
Enzalutamide |
| dc.subject.otherAuthKeyword |
Sipuleucel-T |
| dc.subject.otherChemCAS |
abiraterone, 154229-19-3 |
| dc.subject.otherChemCAS |
abiraterone acetate, 154229-18-2 |
| dc.subject.otherChemCAS |
cabazitaxel, 183133-96-2 |
| dc.subject.otherChemCAS |
denosumab, 615258-40-7 |
| dc.subject.otherChemCAS |
docetaxel, 114977-28-5 |
| dc.subject.otherChemCAS |
enzalutamide, 915087-33-1 |
| dc.subject.otherChemCAS |
mitoxantrone, 65271-80-9, 70476-82-3 |
| dc.subject.otherChemCAS |
prednisolone, 50-24-8 |
| dc.subject.otherChemCAS |
prednisone, 53-03-2 |
| dc.subject.otherChemCAS |
sipuleucel T, 917381-47-6 |
| dc.subject.otherChemCAS |
zoledronic acid, 118072-93-8, 131654-46-1, 165800-06-6, 165800-07-7 |
| dc.subject.otherChemCAS |
Antineoplastic Agents, Hormonal |
| dc.subject.otherIndex |
abiraterone |
| dc.subject.otherIndex |
abiraterone acetate |
| dc.subject.otherIndex |
cabazitaxel |
| dc.subject.otherIndex |
denosumab |
| dc.subject.otherIndex |
docetaxel |
| dc.subject.otherIndex |
enzalutamide |
| dc.subject.otherIndex |
mitoxantrone |
| dc.subject.otherIndex |
placebo |
| dc.subject.otherIndex |
prednisolone |
| dc.subject.otherIndex |
prednisone |
| dc.subject.otherIndex |
prostate specific antigen |
| dc.subject.otherIndex |
radium chloride ra 223 |
| dc.subject.otherIndex |
sipuleucel T |
| dc.subject.otherIndex |
zoledronic acid |
| dc.subject.otherIndex |
advanced cancer |
| dc.subject.otherIndex |
androgen deprivation therapy |
| dc.subject.otherIndex |
asthenia |
| dc.subject.otherIndex |
blood pressure monitoring |
| dc.subject.otherIndex |
bone density |
| dc.subject.otherIndex |
bone metastasis |
| dc.subject.otherIndex |
cancer chemotherapy |
| dc.subject.otherIndex |
castration resistant prostate cancer |
| dc.subject.otherIndex |
cell proliferation |
| dc.subject.otherIndex |
chill |
| dc.subject.otherIndex |
clinical trial (topic) |
| dc.subject.otherIndex |
dehydration |
| dc.subject.otherIndex |
dizziness |
| dc.subject.otherIndex |
drug cost |
| dc.subject.otherIndex |
drug efficacy |
| dc.subject.otherIndex |
drug excretion |
| dc.subject.otherIndex |
drug fatality |
| dc.subject.otherIndex |
drug fever |
| dc.subject.otherIndex |
drug induced headache |
| dc.subject.otherIndex |
drug metabolism |
| dc.subject.otherIndex |
drug safety |
| dc.subject.otherIndex |
drug tolerability |
| dc.subject.otherIndex |
edema |
| dc.subject.otherIndex |
elderly care |
| dc.subject.otherIndex |
fatigue |
| dc.subject.otherIndex |
febrile neutropenia |
| dc.subject.otherIndex |
fluid retention |
| dc.subject.otherIndex |
heart disease |
| dc.subject.otherIndex |
human |
| dc.subject.otherIndex |
hypertension |
| dc.subject.otherIndex |
hypocalcemia |
| dc.subject.otherIndex |
hypokalemia |
| dc.subject.otherIndex |
kidney failure |
| dc.subject.otherIndex |
metastasis |
| dc.subject.otherIndex |
neutropenia |
| dc.subject.otherIndex |
osteoclast |
| dc.subject.otherIndex |
overall survival |
| dc.subject.otherIndex |
pain |
| dc.subject.otherIndex |
progression free survival |
| dc.subject.otherIndex |
prostate cancer |
| dc.subject.otherIndex |
quality of life |
| dc.subject.otherIndex |
review |
| dc.subject.otherIndex |
seizure |
| dc.subject.otherIndex |
sepsis |
| dc.subject.otherIndex |
side effect |
| dc.subject.otherIndex |
spine fracture |
| dc.subject.otherIndex |
treatment response |
| dc.subject.otherIndex |
urinary tract infection |
| dc.subject.otherIndex |
visual analog scale |
| dc.subject.otherIndex |
Aged |
| dc.subject.otherIndex |
Aged, 80 and over |
| dc.subject.otherIndex |
Antineoplastic Agents, Hormonal |
| dc.subject.otherIndex |
Antineoplastic Combined Chemotherapy Protocols |
| dc.subject.otherIndex |
Humans |
| dc.subject.otherIndex |
Immunotherapy |
| dc.subject.otherIndex |
Male |
| dc.subject.otherIndex |
Prostatic Neoplasms |
| dc.subject.otherKeywordPlus |
INHIBITOR ABIRATERONE ACETATE |
| dc.subject.otherKeywordPlus |
I CLINICAL-TRIAL |
| dc.subject.otherKeywordPlus |
PHASE-I |
| dc.subject.otherKeywordPlus |
STEROIDAL INHIBITORS |
| dc.subject.otherKeywordPlus |
ANDROGEN-DEPRIVATION |
| dc.subject.otherKeywordPlus |
ANTITUMOR-ACTIVITY |
| dc.subject.otherKeywordPlus |
POST-DOCETAXEL |
| dc.subject.otherKeywordPlus |
SIPULEUCEL-T |
| dc.subject.otherKeywordPlus |
THERAPY |
| dc.subject.otherKeywordPlus |
CYP17 |
| dc.subject.otherWOS |
Oncology |